NVSEF News and Press, Novartis Ag Basel Akt From 03/23/23

2023-03-23 14:00:00 ET Summary In today’s article, I will present 10 dividend growth companies that I currently consider to be particularly attractive. The 10 selected picks have shown an Average Dividend Growth Rate of 12.92% over the past 5 years. At the same time, th...

Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusion All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including ind...

New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months mPFS for standard of care 1 ,2 Approval also received for liquid for...

2023-03-09 15:42:20 ET TG Therapeutics ( NASDAQ: TGTX ) launched its newly approved multiple sclerosis therapy Briumvi at $59K per year, but an influential U.S. drug pricing watchdog, says that the company should price it between $16.5K – $34.9K to meet cost-effectiveness...

2023-03-06 03:11:42 ET Summary In Q4 2022, the company's revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people's desire to vaccinate against COVID-19. According to the Wall Street Journal, Pfizer's management is in talks t...

Summary With the dollar still strong and inflation fears still looming, now is an especially good time for US investors to buy more foreign dividend stocks. US investors should also consider tax advantages of splitting international dividend stock exposure between taxable and tax-shelte...

Summary Viatris' gross margin reached its highest level since its inception in the fourth quarter of 2020, despite rising raw material and labor costs. On February 27, 2023, Viatris management will publish financial results for the 4th quarter of 2022. Viatris' operating income for ...

Summary Bristol-Myers Squibb's revenue was $11,406 million in Q4 2022, showing mixed results compared to previous quarters, and there are many explanations for this, which will be discussed in the article. In 2023, the company's investors should receive a dividend of $2.28 per share, up...

Summary This article is the first of a 3-part series discussing 10 sectors that could provide high returns in the future. This first part covers Artificial Intelligence (AI) and Healthcare Technology, highlighting companies and potential growth opportunities. We discuss why you shou...

Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...